Radiopharmaceuticals Market
2019 Analysis and Review of Radiopharmaceuticals Market by Application - Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, and Nephrology for 2019 - 2029
- 2019-11-28
- REP-GB-1992
- 40 Tables
- 106 Figures
- 190 pages
-
An Incisive, In-depth Analysis on the Radiopharmaceuticals Market
This study offers a comprehensive, 360 degree analysis on the Radiopharmaceuticals market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Radiopharmaceuticals market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.
COVID -19 : Impact Analysis
Request the coronavirus imapact analysis across industries and markets
Request Covid -19 ImpactKey Growth Influencers - Radiopharmaceuticals Market
Rising Prevalence of Cancers and Cardiovascular Diseases
Prevalence of diseases such as cancer and cardiovascular diseases are increasing rapidly across the globe due to aging population, unhealthy food habits, and rising obesity. For instance, according to the American Heart Association, cardiovascular diseases alone accounts for 17.3 million deaths each year, which is more than the deaths caused due to cancer.
Radiopharmaceuticals provides an upper hand to radiologists over the conventional medicines to treat such diseases owing to benefits provided by radiopharmaceuticals such as targeted therapy. Such advantages are expected to boost the radiopharmaceuticals market. Moreover, according to the Healthcare Quality Improvement Partnership (HQIP) report, approximately 9,200 new cases of head and neck cancers are diagnosed in England and Wales each year. Rising situations like this is anticipated to boost the growth of radiopharmaceuticals market, globally.
Numerous Diagnostic Applications Surging Market Growth
Radiopharmaceuticals play an imperative role in diagnosis of several diseases by providing better understanding of disease staging. Radiopharmaceuticals linked to chemical compounds permit specified physiological process to be scrutinized. Advantages of radiopharmaceuticals such as high efficacy and non-invasive external monitoring have increased global radioisotope production for usage in molecular imaging and in therapeutic nuclear medicines. Such benefits are anticipated to fuel the market growth for radiopharmaceuticals.
According to the World Nuclear Association, radioisotopes are used in medicine in over 10,000 hospitals across the world and 90% of the procedures involve diagnosis of infectious diseases, cancer, neurological disorders, etc. The diagnostic use of radiopharmaceuticals is more varied and complex and at the same time constitute a significant growth in nuclear imaging industry.
Increased Focus on Centralized Pharmacies
In the radiopharmaceutical industry there is a lack of formalized GMP guidelines along with stringent regulations governing the use of radiopharmaceuticals. However, to address the quality assurance for radiopharmaceuticals, many nuclear medicine physicians are recommending setting up centralized radio-pharmacies. This is because of the growing interest from administrators and legislators in context with regulations for radiopharmaceuticals, Positron Emission Tomography (PET), and for clinical trials. A centralized radio pharmacy model imposes several advantages to patients as well as facilities including minimizing the radiation exposure with ability to dispense patient specific prescription, delivering specified products from all sources and services available.
Short Half-Life Restricting Supply of Radioisotopes
Supply of radioisotopes is unstable globally and is expected to reduce in the near future due to shut down of major reactors in places such as Canada and Holland. Short half-life radioisotopes cannot be supplied to other regions where the production of raw materials is negligible, as it disintegrates rapidly. According to the Nuclear Energy Agency (NEA), supply of radioisotopes started deflating from 2016, not simply from reactors, but also due to processing limitations such as transport and demand management. Such factors are anticipated to hamper the market growth.
Radiopharmaceuticals Market Structure Analysis
- The global radiopharmaceuticals market is a fairly consolidated industry. The global market is dominated by top five players accounting for around 90% market share.
- Leading companies such as Siemens (Siemens Healthineers) and GE Healthcare garners around 2/3rd of the total radiopharmaceuticals market share.
- Business expansion through investing in emerging economies and increased capital expenditure in research and development initiatives are policies pursued by major participants in the radiopharmaceuticals market.
FREQUENTLY ASKED QUESTIONS ABOUT RAdIOPHARMACEUTICALs MARKET
Will rise in number of install base equipment affect growth of the radiopharmaceuticals market?
Widespread availability of the SPECT and PET scanning machines will result in to growing number of radio diagnostic and radio therapeutics events globally. For instance, the number of PET scanning machines installed per head of population in North America are more as compared to that installed in Europe thus leading to increased usage of radiotracers in the region.
How stringent regulations are hampering launch of new products?
Production, storage, and usage of radioisotopes require proper precautions because radioisotopes generate radiation which can affect mass population and the environment. Approval from the Food and Drug Administration, Medicines and Healthcare Products Regulatory Agency is mandatory for any usage, storage, or production of radioisotopes.
Which is emerging radioisotopes for therapeutic purpose?
Iodine-131, a therapeutic radiotracer continues to be ideal tracer for the treatment of not only thyroid cancer but also other therapeutic indications and is being slowly replaced by Lutetium-177 (Lu-177). Lu-177, low-energy β-particle emitter is identified to be one of the emerging radiotracer for treatment of metastatic castrate-resistant prostate cancer (mCRPC) and neuroendocrine tumors.
Which region will offer more lucrative opportunities for radiopharmaceutical market players?
South Asia’s radiopharmaceutical market expected to show significant growth over the forecast period, owing to rising healthcare infrastructure in India and ASEAN countries. India, China and Brazil remain top three target geographies of leading manufacturers to expand their regional presence.
Which are key market radiopharmaceutical brands?
Xofigo by Bayer AG, Lutethera by Novartis AG, Vizamyl by GE Helathcare and Fludeoxyglucose F 18 Injection by Siemens AG are key marketed radiopharmaceutical brands. This brands estimated to cover around half of the market share.
What are the key product development strategies followed by leading manufacturer
Manufacturers of radiopharmaceuticals are mainly focused on developing novel diagnostic as well as therapeutic radiopharmaceuticals with low pricing in order to increase sales and in turn garner larger market share.
Radiopharmaceuticals Market Analysis 2019 - 2029
A recent market study published by Future Market Insights on the radiopharmaceuticals market includes global industry analysis for 2014 - 2018 & opportunity assessment for 2019 - 2029, and delivers a comprehensive assessment of the most important market dynamics. After conducting a thorough research on the historical as well as current growth parameters of the radiopharmaceuticals market, the growth prospects of the market are obtained with maximum precision.
Radiopharmaceuticals Market: Segmentation
The global radiopharmaceuticals market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Radioisotope |
Application |
Source |
End User |
Region |
|
|
|
|
|
Report Chapters
Chapter 01 – Executive Summary
The report initiates with the executive summary of the radiopharmaceuticals market, which includes a summary of key findings and statistics of the market. It also includes drivers and trends pertaining to the radiopharmaceuticals market.
Chapter 02 – Market Overview
Readers can find the definition and a detailed segmentation of the radiopharmaceuticals market in this chapter, which will help them understand the basic information about the radiopharmaceuticals market. Along with this, comprehensive information pertaining to radiopharmaceuticals and their properties are provided in this section. This section also highlights the inclusions and exclusions, which helps the reader understand the scope of the radiopharmaceuticals market report.
Chapter 03 – Market Dynamics
This section gives information about drivers, and restraints of the radiopharmaceuticals market. This section also includes various opportunities and key trends of the radiopharmaceuticals market.
Chapter 04 – Market Context
This section gives information about upcoming pipeline products, PEST analysis, Porter’s Five Forces Model, and regulatory scenario of the radiopharmaceuticals market.
Chapter 05 – Global Radiopharmaceuticals Market Demand Analysis 2014 - 2018 & Opportunity Assessment 2019 - 2029
This section explains the global market value analysis and forecast for the radiopharmaceuticals market between the forecast periods of 2019 - 2029. This chapter includes a detailed analysis of the historical radiopharmaceuticals market, along with an opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2019), and an incremental $ opportunity for the forecast period (2019–2029).
Chapter 06 – Global Radiopharmaceuticals Market Analysis 2014 - 2018 & Opportunity Assessment 2019 - 2029, by Radioisotope
Based on radioisotope, the radiopharmaceuticals market is segmented into Technetium-99, Fluorine-18, Iodine-131, Leutetium-177, Yttrium-90, Gallium-68, Gallium-67, Rubidium-82, Iodine-123, Iodine-125, Indium-111 and others. In this chapter, readers can find information about the key trends and developments in the radiopharmaceuticals market and market attractiveness analysis based on radioisotope.
Chapter 07 – Global Radiopharmaceuticals Market Analysis 2014 - 2018 & Opportunity Assessment 2019 - 2029, by Application
Based on application, the radiopharmaceuticals market is segmented into oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology and others. In this chapter, readers can understand the market attractive analysis based on application.
Chapter 08 – Global Radiopharmaceuticals Market Analysis 2014 - 2018 & Opportunity Assessment 2019 - 2029, by Source
Based on application, the radiopharmaceuticals market is segmented into cyclotrons and nuclear reactors. In this chapter, readers can understand the market attractive analysis based on source.
Chapter 09 – Global Radiopharmaceuticals Market Analysis 2014 - 2018 & Opportunity Assessment 2019 - 2029, by End User
This chapter provides details about the radiopharmaceuticals market based on the end user, and has been classified into hospitals, diagnostic imaging centers, ambulatory surgical centers and cancer research institutes. In this chapter, readers can understand the market attractive analysis based on end user.
Chapter 10 – Global Radiopharmaceuticals Market Analysis 2014 - 2018 & Opportunity Assessment 2019 - 2029, by Region
This chapter explains how the radiopharmaceuticals market will grow across various geographic regions such as North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan (APEJ), Japan, and Middle East & Africa (MEA).
Chapter 11 – North America Radiopharmaceuticals Market Analysis 2014 - 2018 & Opportunity Assessment 2019 - 2029
This chapter includes a detailed analysis of the growth of the North America Radiopharmaceuticals market, along with a country-wise assessment that includes the U.S. and Canada. Readers can also find the regional trends, and market growth based on the radioisotope, application, source, end user, and countries in North America.
Chapter 12 – Latin America Radiopharmaceuticals Market Analysis 2014 - 2018 & Opportunity Assessment 2019 - 2029
This chapter provides the growth scenario of the radiopharmaceuticals market in Latin American countries such as Brazil, Mexico, and the Rest of Latin America. Along with this, assessment of the market across target segments has been provided.
Chapter 13 – Western Europe Radiopharmaceuticals Market Analysis 2014 - 2018 & Opportunity Assessment 2019 - 2029
Important growth prospects of the radiopharmaceuticals market based on its end users in several countries such as the U.K., France, Germany, Spain, Italy, Nordic Countries, Benelux and the Rest of Western Europe are included in this chapter.
Chapter 14 – Eastern Europe Radiopharmaceuticals Market Analysis 2014 - 2018 & Opportunity Assessment 2019 - 2029
Important growth prospects of the radiopharmaceuticals market based on its end users in several countries such as Russia, Poland and the Rest of Eastern Europe are included in this chapter.
Chapter 15 – Asia Pacific excluding Japan (APEJ) Radiopharmaceuticals Market Analysis 2014 - 2018 & Opportunity Assessment 2019 - 2029
In this chapter, China, India, Australia and New Zealand, ASEAN and Rest of Asia Pacific countries are the prominent countries in the Asia Pacific excluding Japan region that are the prime subjects of assessment to obtain the growth prospects of the APEJ radiopharmaceuticals market. Readers can find detailed information about the growth parameters of the APEJ radiopharmaceuticals market during the forecast period of 2019 - 2029.
Chapter 16 – Japan Radiopharmaceuticals Market Analysis 2014 - 2018 & Opportunity Assessment 2019 - 2029
This section highlights the growth prospects of the radiopharmaceuticals market for Japan, during the forecast period of 2019 - 2029.
Chapter 17 – MEA Radiopharmaceuticals Market Analysis 2014 - 2018 & Opportunity Assessment 2019 - 2029
This chapter provides information about how the radiopharmaceuticals market will grow in major countries in the MEA region such as GCC Countries, South Africa, and the Rest of MEA, during the forecast period of 2019 - 2029.
Chapter 18 – Competition Analysis
In this chapter, readers can find a comprehensive list of all the prominent stakeholders in the radiopharmaceuticals market, along with a detailed information about each company, which includes company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured in the report are GE Healthcare, Siemens (Siemens Healthineers), Novartis (Advanced Accelerator Applications), Lantheus Holdings, Inc., Eckert & Ziegler, Positron Corporation, Bayer AG, Curium and Sotera Health LLC (Nordion, Inc.).
Chapter 19 – Assumptions and Acronyms
This chapter includes a list of acronyms and assumptions that provides a base to the information and statistics included in the radiopharmaceuticals market report.
Chapter 20 – Research Methodology
This chapter help readers understand the research methodology followed to obtain various conclusions as well as important qualitative and quantitative information about the radiopharmaceuticals market.
Sources and Primary Research Splits (%)
Industry Interactions
- C - Level Executives
- Marketing Directors
- Product Managers
- Business Development Officers
- Production Managers
- Procurement Heads
- Sales Executives
- Distributors
- Traders
- Raw Material Suppliers
- Industry Experts
- End Users
- Current Market Dynamics and Challenges
- Yesteryear Trends
- Market Characteristics
- Market Performance and Growth Quadrants
- Competition Structure and Market Structure
- Strategic Growth Initiatives
- Near-term and Long-term Market Growth Prospects
- Market Segment Splits and Authenticity
- Opinions on Market Projections and Validity of Assumptions
References Catalogue
- Industry Publications
- BioMed Research International
- ACS Publications
- European Journal of Nuclear Medicine
- Industry Associations
- International Atomic Energy Agency
- American Heart Association
- World Nuclear Association
- Society of Nuclear Medicine and Molecular Imaging
- Factiva
- Company Press Releases
- Annual Reports and Investor Presentations
- Research Papers
- Government Websites and Publications
- Trade Websites
Get in touch
Harish Tiwari
Global Head - Business Development
Our Clients
CASE STUDIES
See how our work makes an impact.
At FMI, we design strategies that are adaptive, impactful, and implementable.